Instruction 1(b).

П

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response	: 0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> Nuzum Charles Lee Sr				2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Predictive Oncology Inc.</u> [POAI]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
					-	-	X	Director	10% 0	Dwner				
(Last) 23 BROOKL	(First) INE DRIVE	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/01/2022						Officer (give title below)	Other below	(specify /)		
		4. lf A	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable					
(Street)									Line)					
NOVATO	СА								Form filed by One Reporting Person					
										Form filed by Mo Person	re than One Re	porting		
(City)	(State)	(Zip)												
		Table I - Non-De	erivative S	ecurities Acq	uired,	Dis	posed of, o	or Ber	eficially	Owned				
Date		Transaction Te Onth/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
					Code	v	Amount	(A) or	Price	Transaction(s)		(Instr. 4)		

									(U)		(instr. 3	and 4)		
Common Stock 07/01/2022						Α		44,704	A	\$ <mark>0</mark>	330	),868	D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative	Conversion	3. Transaction Date	3A. Deemed Execution Date,	4. Transaction	5. Number of	Expirati	ion Date		7. Title an Amount o	f De	rivative	9. Number o derivative	f 10. Ownership	11. Nature of Indirect

Security (Instr. 3)	or Exercise Price of Derivative Security	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Code (	ode (Instr.   Derivative   (Me		Expiration Da (Month/Day/Y	Amount or Securities Underlying Derivative Security (Instr. 3 and 4)		Security (Instr. 5)	Gerivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form: Direct (D) or Indirect (I) (Instr. 4)	of indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					

Explanation of Responses:

/s/ Charles L. Nuzum

07/05/2022 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.